Maintenance: the part nobody writes about

The silence after the change

I am Benedikt, and I hold the circles the internet is worst at. Everything written about these medications is about starting: the first pen, the first twelve weeks, the early change, the difficult months. Then the writing stops. And the actual majority of your time on this — or off it — happens in the silence afterwards.

Members arrive in maintenance with a very particular kind of disorientation. Something that occupied their whole attention for a year has quietly become uneventful, and nobody prepared them for uneventful. There is no new symptom to research, no step up to worry about, no change to report. Appointments get shorter. People stop asking. And a person who had been living inside a project finds themselves living inside a Wednesday.

That sounds like a good problem and it does not always feel like one. Several members describe a flat patch somewhere in the second year that had nothing to do with the medicine and everything to do with the absence of a story. Ollie put it as: I did not know what to do with myself once it stopped being interesting.

The honest headline of this whole guide is that in maintenance, the news is usually that there is no news, and learning to find that acceptable is most of the work.

Where the evidence actually stops

I want to be precise about this, because vague confidence is how people get hurt and there is a great deal of vague confidence about the long term.

The large weight-management trials ran roughly sixty-eight to seventy-two weeks. That is about a year and a third. Everything past that point in your life is outside the evidence that made these drugs famous. There are extension studies, there are diabetes datasets running considerably longer, and there are outcome trials that followed people for several years for cardiovascular endpoints — so it is not a void. But the specific question most members are actually asking, which is what does year four look like for someone like me, has not been answered because it has largely not been studied.

What we do have on maintenance specifically is useful and narrow. A trial that switched people to placebo after several months found that most of the change reversed over the following year. A tirzepatide trial with a randomised withdrawal found the same pattern: continued treatment held the change, withdrawal did not. Follow-up after the semaglutide trial ended found most of the reduction returned within a year off treatment, along with the cardiometabolic improvements reverting towards where they started.

Read together, those say something clear and uncomfortable: for most people, this behaves like a treatment for an ongoing condition rather than a course of something. Stopping generally means the effect stops too.

Everyone is improvising, including your clinician

Because the evidence thins, maintenance practice varies enormously and is being worked out in real time. Some prescribers keep people at the dose that produced the change. Some reduce to a lower maintenance dose. Some try longer intervals between doses. Some have people come off entirely and see. All of these are being done, right now, to people in our circles, and there is very little published to say which is best.

I say this not to alarm you but so that you stop assuming there is a settled protocol you have not been told about. There is not. If your clinician sounds uncertain, that is honesty rather than incompetence, and the ones who sound completely certain are usually the ones to ask more questions of.

What that means practically is that you are a participant in the decision rather than a recipient of it. Useful questions to bring: what would make you change my dose in either direction, what would you like me to watch for, how often will we review this, and what happens if there is a supply problem. Talking to your GP when time is short and the appointment questions tool both help with getting that into nine minutes.

And be wary of the confident stranger. Maintenance is where the largest amount of invented protocol circulates, precisely because the evidence is thin enough that nobody can be immediately contradicted.

What a steady year actually feels like

Collected from members several years in, because almost nobody describes this and people arrive expecting something else.

• Appetite signalling settles into a new normal that is neither the loud version from before nor the total quiet of the first months. Many members describe a middle state they find quite ordinary and slightly hard to explain to anyone.
• Some hunger comes back. This frightens people badly and is usually not a sign that anything has stopped working. Food noise covers the phenomenon.
• Side effects generally become minor or disappear. Constipation is the one that most often persists, unglamorously, for years.
• The weekly injection becomes a fact about your Wednesdays. Members forget whether they have done it, which is why the calendar note matters more in year three than in month one.
• Weight fluctuates. It goes up and down within a range, as bodies do, and the first upward wobble after a long steady stretch causes disproportionate panic in nearly everybody.
• The medical relationship changes. Reviews get shorter and less interested. Some members find that a relief and some find it neglectful.

Plateaus is the adjacent page, and the distinction between a plateau and maintenance is largely one of intention.

The psychological work of no news

This is the part I spend most of my circle time on and it is barely written about anywhere.

If you spent a year measuring your life in change, the end of change removes your entire measuring apparatus at once. People respond in fairly predictable ways. Some go looking for a new project and start pushing for further change they did not originally want, which is worth noticing carefully — it is one of the routes by which a health decision quietly turns into something else, and Jonah’s ed-recovery-aware circle sees the far end of it. Some become vigilant, checking constantly for signs of reversal. Some feel flat and cannot say why, having got exactly what they set out for.

What helps, from the circle: deliberately changing what you measure. Members who moved to non-scale markers — what they can do, how they sleep, what their reviews show, whether the stairs are still easy — report a much steadier second year than those who kept the original measure and watched it not move.

Also: keeping a reason to attend. A lot of people drift away from support in maintenance because nothing is wrong, and then have nobody when something is. The maintenance circle is deliberately low-intensity for this reason. People come, say very little, and stay on the list.

Cost, supply and the years ahead

The dullest part of maintenance is the one that ends it most often. If you are paying out of pocket, this is an indefinite recurring cost, and members who have been going for years describe budget fatigue as harder to manage than any symptom. If you are insured or on a public scheme, coverage rules change, and they change in ways that are not aimed at you personally but land on you personally.

Shortages are the other recurring shock. They have happened repeatedly and will happen again, and a shortage in maintenance feels quite different from a shortage in month two, because you have built a life around this. Have a plan before you need one: know what your prescriber would do, know what your options are, and read shortages and substitutions while nothing is wrong.

Petra’s paying-out-of-pocket and insurance-appeals circles are both full of people in exactly this position, and an appeal that failed two years ago is often worth running again under changed criteria.

If you are considering stopping — for cost, for side effects, by choice, or because someone else decided — coming off, what to expect is written clear-eyed and without treating return as failure. I will not allow that framing in my circle and I have had the argument more than once.

What I would want you to take away

That maintenance is a legitimate destination rather than a waiting room. That the absence of news is the good outcome, even though it does not feel like one for a while.

That you are past the edge of the evidence and so is everybody else, including the confident people, and the correct posture there is curiosity and regular review rather than certainty.

That an upward wobble is a wobble. That coming off is a normal thing that people do, that regain afterwards is common and documented rather than shameful, and that restarting is so ordinary that it needed its own circle.

And that year three is worth having company for. Nobody writes about year three. We write about year three, on a Tuesday, with about eleven people and quite long silences, and it is the best circle I hold.